Abstract. Hypoxia-induced gene expression frequently occurs in malignant solid tumors because they often have hypoxic areas in which circulation is compromised due to structurally disorganized blood vessels. Hypoxia-response elements (HREs) are responsible for activating gene transcription in response to hypoxia. In this study, we constructed a hypoxia-response plasmid vector producing short hairpin RNA (shRNA) against B-cell leukemia/lymphoma-2 (bcl-2), an anti-apoptotic factor. The hypoxia-response promoter was made by inserting tandem repeats of HREs upstream of cytomegalovirus (CMV) promoter (HRE-CMV). HRE-CMV shbcl-2 vector consisted of bcl-2 shRNA under the control of HRE-CMV promoter. In hypoxic mouse rectum carcinoma cells (colon-26), the production of bcl-2 shRNA driven by HRE-CMV promoter was approximately 2-fold greater than that driven by CMV promoter. A single intratumoral (i.t.) injection of 40 μ g HRE-CMV shbcl-2 to colon-26 tumor-bearing mice caused apoptotic cell death, and repetitive treatment with HRE-CMV shbcl-2 (40 μ g/mouse, i.t.) also significantly suppressed the growth of colon-26 tumor cells implanted in mice. Apoptotic and anti-tumor effects were not observed in tumor-bearing mice treated with CMV shbcl-2. These results reveal the ability of HRE-CMV shbcl-2 vector to suppress the expression of bcl-2 in hypoxic tumor cells and suggest the usefulness of our constructed hypoxia-response plasmid vector to treat malignant tumors.
Introduction
RNA interference (RNAi) is post-transcriptional gene silencing in a sequence-specific manner (1) . RNAi techniques have entered the limelight not only as a tool in gene analysis but also as therapeutic agents for gene-related diseases, such as cancers, neurodegenerative diseases, and virus infections (2 -4) . Gene silencing is triggered by double-stranded RNA (dsRNA) through utilization of an intrinsic gene silencing mechanism that proceeds via two steps (5) . In the first step, dsRNA is recognized by RNase III family nuclease and cleaved into approximately 19 -23 nt small interfering RNA (siRNA). siRNAs are incorporated with other factors into an RNA-induced silencing complex (RISC) that identifies a complementary sequence to the slice target of mRNAs. Sliced mRNAs decrease its stability and are degraded by intrinsic nucleases; however, the induction of RNAi in normal cells may cause undesirable effects when the target gene is a key determinant of normal cell function. Consequently, it is important to control the delivery and expression of siRNA efficiently in target cells.
Recent studies have demonstrated that a vector-based RNAi system can induce gene silencing in mammalian cells (6 -8) . Short hairpin RNAs (shRNAs), a precursor of siRNA, are driven by type III RNA polymerase (Pol III)-or type II RNA polymerase (Pol II)-based plasmid vector through a transcriptional process (9 -11) . In all types of cells, Pol III has high transcriptional activity of essential small RNAs: tRNAs, 5S RNA, and U6 snRNA. On the other hand, Pol II promoter could regulate shRNA expression in specific tissues. Several studies have reported the construction of vectors producing shRNA, which are driven by a cell-or tissue-specific promoter (12, 13) . In these studies, specific promoters are constructed by inserting 5′-flanking regions of tissue-specific genes, which enable the production of shRNA in a tissuedependent manner.
A variety of particular DNA sequences are identified as response elements related to cell-or tissue-specific gene expression. It has been revealed that there is a distinct transcriptional mechanism in tumor cells (14) . Although normal tissue is supplied with enough oxygen through well-developed blood vessels, solid tumor tissue is often under hypoxic conditions resulting from high interstitial pressure and abnormal structure of neovessels (14) . Regardless of a severe condition, hypoxic tumor cells enhance the expressions of hypoxia response genes (e.g., glucose transporter 1, vascular endothelial growth factor, and erythropoietin) to survive and proliferate further. The hypoxia response element (HRE) is responsible for activating the transcription of hypoxia-induced gene expression (15) . Hypoxia inducible factor 1 (HIF-1) functions as a heterodimer consisting of two basic-helixloop-helix proteins, including HIF-1 α and aryl hydrocarbon receptor nuclear translocator (ARNT, called HIF-1 β ). HIF-1 α is degraded oxygen-dependently by prolyl hydroxylase within 5 min under normoxic conditions (16) . However, under hypoxic conditions, HIF-1 α is stabilized and translocated from the cytoplasm to the nucleus to interact with ARNT. The HIF-1 and CBP/p300 complex binds to HRE and enhances the transcription of hypoxiaresponse genes. To date, some reports have demonstrated that HRE has high transcriptional activity under hypoxic conditions (15) .
Colon cancer is a major malignant cancer because of its vigorous cell proliferation and metastasis. Moreover, colon cancer achieves drug resistance by expressing efflux transporters such as ATP binding cassette transporter (17) . As a consequence, new strategies are required to treat colon cancers. The B-cell leukemia/lymphoma-2 (bcl-2) gene is an anti-apoptotic factor related to drug resistance in cancers (18) . Bcl-2 protein inhibits the release of cytochrome c from mitochondria to the cytoplasm through a voltage-dependent anion channel (VDAC) (19) , which activates proteolytic enzymes known as caspases. Several studies have indicated that bcl-2 is a promising target of cancer therapy. bcl-2 gene silencing not only induces the apoptosis of cancer cells but also increases chemosensitivity (20, 21) . On the other hand, bcl-2 has important functions for the normal development of normal tissues. Newborn bcl-2 knockout mice are viable, but almost all die within a few weeks. Growth retardation, polycystic kidneys, atrophy of the thymus and spleen, abnormal small intestine, bone deposition, and hypopigmented hair are observed in bcl-2 knockout mice (22 -24) . It is conceivable that bcl-2 gene silencing in normal healthy tissues induces undesirable effects. Controllable suppression of bcl-2 expression is required for colon cancer therapy.
In this study, we applied the HIF-1/HRE gene expression system to produce bcl-2 shRNA in hypoxic tumor cells. A new synthetic promoter was constructed by inserting synthetic tandem repeats of four HREs upstream of the cytomegalovirus (CMV) promoter. The apoptotic effect of the hypoxia-response plasmid vector in colon-26 cells was evaluated under hypoxic conditions.
Materials and Methods

Cells and animals
Colon-26, mouse rectum carcinoma cell lines, were obtained from the Cell Resource Center for Biomedical Research, Tohoku University (Sendai) and cultured under a 5%-CO 2 environment at 37°C in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). In the present study, hypoxic experiments were performed by treating the cells with Cobalt (II) Chloride (CoCl 2 ) (Nacalai Tesque, Kyoto), a chemical that mimics hypoxia. The imitation of hypoxic conditions by CoCl 2 treatment was confirmed by the accumulation of HIF-1 α protein.
Male BALB/c mice (4 weeks of age) were purchased from Charles River Japan, Inc. (Kanagawa). They were housed under a standardized light/dark cycle at room temperature of 24 ± 1°C and humidity of 60 ± 10% with food and water ad libitum. A 25-μ l volume containing 5 × 10 5 viable colon-26 cells was injected into the right hind footpads of each mouse. Tumor-bearing mice were used after the tumor size reached approximately 50 mm 3 .
Experimental design
To construct the HRE-CMV promoter, synthetic HREs were inserted upstream of CMV promoter (Fig. 1A) . The shRNA expression vectors targeting the bcl-2 gene (HRE-CMV shbcl-2 or CMV shbcl-2) were constructed by insertion of designed shRNA coding sequences into the downstream of HRE-CMV or CMV promoter (without HREs). To explore the influence of HRE-CMV promoter on shRNA production under the hypoxic condition, bcl-2 shRNA expression vectors were transfected into colon-26 cells, and cells were incubated in the presence or absence of CoCl 2 . At 48 h after transfection, bcl-2 shRNA was detected by one-step RT-PCR. To investigate the influence of HRE-CMV shbcl-2 on gene silencing in CoCl 2 -treated cells, bcl-2 shRNA expression vector was transfected into colon-26 cells, and cells were incu-bated in the presence or absence of CoCl 2 . At 48 and 72 h after transfection, the levels of bcl-2 mRNA and its protein was assessed by real-time PCR and Western blotting, respectively. To test whether interferon response was induced by transfecting the cells with shRNA expression vectors, oligoadenylate synthetase 1b (oas1b) mRNA was assessed by real-time PCR. To explore the time course of the gene-silencing effect of bcl-2 shRNA in tumor cells, mRNA levels of bcl-2 after a single intratumoral injection of HRE-CMV shbcl-2 or CMV shbcl-2 (40 μ g/mouse) were measured by real-time PCR. To observe the induction of apoptotic cell death by bcl-2 gene silencing, DNA fragmentation was visualized by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. To test the ability of HRE-CMV shbcl-2 to suppress tumor growth, colon-26 tumor-bearing mice received an intratumoral injection of shRNA expression vectors (40 μ g/mouse) once every other day, five times.
Construction of shRNA expression vectors
To construct the HRE-CMV promoter, an oligonucleotide containing tandem repeats of HREs (5′-ACGTG-3′) was synthesized as reported previously (25) . As shown in Fig. 1A , HRE-CMV promoter was constructed by inserting four synthetic HREs upstream of the CMV promoter of pcDNA3.1 vectors (Invitrogen, Carlsbad, CA, USA). The mixture of equal parts of 0.3 mM HRE oligonucleotides dissolved in annealing buffer (0.1 M TrisHCl, 50 mM MgCl 2 , pH 8.0) was heated to 95°C for 2 min and annealed from 95°C to 20°C during a half an hour. The self-complementary oligonucleotides were ligated into pcDNA3.1 vector, linearized with Mlu I by using the LigaFast TM Rapid DNA Ligation System (Promega, Madison, WI, USA). In brief, the mixture of 200 ng of linear pcDNA3.1, 0.015 nmol of self-complementary oligonucleotides, 5 μ l of 2× Rapid Ligation Buffer, and 2 μ l of T4 DNA Ligase was incubated at 16°C for 1 h. Clones were confirmed to insert the designed sequences by sequencing. To construct the shRNA expression vector, target sequences of bcl-2 (GenBank accession no. NM_009741) and lacZ (GenBank accession no. M16485.1) were designed by BLOCK-iT RNAi designer (Invitrogen). The shRNA coding sequences were inserted downstream of HRE-CMV or CMV promoter of pcD-NA3.1 vectors. The mixture of equal parts of 0.3 mM shRNA coding sequences solved in annealing buffer was heated to 95°C for 2 min and annealed from 95°C to 20°C during a half an hour. The self-complementary oligonucleotides were ligated into pcDNA3.1 vector after digestion of the vector multiple cloning site with Nhe I and Pme I. The ligation reaction was performed by using the LigaFast TM Rapid DNA Ligation System (Promega). The mixture of 200 ng linear pcDNA3.1, 0.015 nmol of self-complementary oligonucleotides, 5 μ l of 2× Rapid Ligation Buffer, and 2 μ l of T4 DNA Ligase was incubated in 16°C for 1 h. Clones were confirmed to insert the designed sequences by sequencing. The shRNA is required to be a minimal construct because overhangs at the 5′ and 3′ ends of shRNA weaken the gene-silencing effect in vector-based RNAi (8, 26) .
Plasmid transfection
In an in vitro experiment, colon-26 cells were seeded (4 × 10 5 cells/well) into 6-well plates containing 2 ml of RPMI-1640 medium supplemented with 10% FBS one day before transfection. Cells were transfected with shRNA expression vectors (HRE-CMV shbcl-2 or CMV shbcl-2) using Lipofectamine LTX and PLUS Reagents (Invitrogen). In brief, 2 μ g shRNA expression vector was diluted in 50 μ l Opti-MEM I Reduced Serum Medium (Invitrogen) and then 6 μ l PLUS Reagent was added. Subsequently, 50 μ l Opti-MEM containing 4 μ l Lipofectamine LTX were added to the diluted DNA solution. After incubation for 30 min at room temperature, 100 μ l DNA-lipid complex were added to the well containing 1 ml Opti-MEM I Reduced Serum Medium. At 24 h after transfection, Opti-MEM I Reduced Serum Medium was changed to 1 ml RPMI-1640 medium containing 10% FBS. The shRNA-transfected cells were incubated in the presence or absence of 100 μ M CoCl 2 for the indicated time.
In an in vivo experiment, we used HVJ (hemagglutinating virus of Japan)-Envelope (HVJ-E) (Ishihara Sangyo Kaisha, Ltd., Osaka) as a gene transfection reagent because Lipofectamine LTX and PLUS Reagent is off-label for use in an in vivo study. For preparation, 40 μ l of HVJ-E was centrifuged at 12,000 rpm for 5 min. The HVJ-E pellet was suspended in 10 μ l plasmid DNA solution (4 μ g/ μ l in TE buffer) on ice and added with 1 μ l Reagent B. The mixture of HVJ-E-plasmid DNA was centrifuged at 12,000 rpm for 5 min. The pellet of encapsulated vector was suspended in 10 μ l accessory Buffer solution. The 10 μ l encapsulated vectors were injected intratumorally into colon-26 tumor-bearing mice.
RT-PCR analysis
Total RNA was extracted from cultured cells and implanted colon-26 tumor masses using RNAiso (Takara Bio, Otsu). The cDNA of bcl-2 shRNA and mouse β -actin (GenBank accession no. NM_007393) were synthesized and amplified using SuperScript TM One-Step RT-PCR with Platinum ® Taq (Invitrogen). To evaluate the quantitative reliability of the validity of RT-PCR, we performed kinetic analysis of amplified products to ensure that signals were derived only from the exponential phase of amplification. The ratio of the amplified shRNA to the amplified internal control was compared between groups. The cDNA of mouse bcl-2, mouse oas1b (GenBank accession no. AF466822), and mouse β -actin were synthesized using a random primer (hexadeoxyribonucleotide RT-PCR Kit II (Perfect Real Time) (Takara Bio) using the 7500 Real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). We evaluated the validity of quantitative PCR methods using real-time PCR. The ratio of amplified bcl-2 mRNA or oas1b mRNA to amplified β -actin was compared between groups.
Western blot analysis
Whole or nuclear fractions were prepared from cultured cells, implanted colon-26 tumor masses, or healthy tissues (liver, kidney, and brain). Each fraction was obtained by homogenation with lysis buffer [50 mM TrisHCl (pH 8.0), 10 mM EDTA, 1% SDS, 1 mM PMSF, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin] or NE-PER ® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Inc., Rockford, IL, USA) according to the manufacturer's instructions. Lysates containing 20 μ g protein were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was reacted with antibodies against HIF-1 α (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or Bcl-2 (Santa Cruz Biotechnology). Specific antigen-antibody complexes were visualized using horseradish peroxidaseconjugated secondary antibodies and Chemi-Lumi One (Nacalai Tesque).
TUNEL staining
Tumor masses were excised and fixed with phosphatebuffered 10% formalin. Fixed samples were dehydrated by immersing in 10% sucrose PBS for 12 h and 20% sucrose PBS for 12 h at 4°C. Tumor masses were sliced into 10-μ m sections. Sliced samples were labeled with TdT-mediated dUTP using an In situ Apoptosis Detection Kit (Takara Bio) according to the manufacturer's instructions. Tumor sections were observed by fluorescence microscopy.
Determination of antitumor effect
Colon-26 tumor-bearing mice received intratumoral injections of 10 μ l of HVJ-E encapsulated with shRNA expression vectors once every other day five times. A single injection of HVJ-E contained 40 μ g of shRNA expression plasmids as described above. The estimation of tumor volume was performed as described previously (27) . Tumor size was determined with a caliper measur-ing the largest diameter of the major (a) or minor axis (b) and the perpendicular diameter (c). Tumor volume was estimated according to the following formula: tumor volume (mm 3 ) = ( π × a × b × c) / 6.
Statistical analyses
The statistical significance of differences was analyzed by ANOVA and Dunnett's test or the Bonferroni/Dunn test among multiple groups and Student's t -test between groups. A 5% level of probability was considered significant.
Results
HRE-CMV promoter enhances gene-silencing effects of bcl-2 shRNA in CoCl 2 -treated colon-26 cells
We first tested whether the insertion of HREs with CMV promoter could enhance production of shRNA under hypoxic conditions. Treatment of cultured colon-26 cells with CoCl 2 resulted in the accumulation of HIF-1 α protein in a dose-dependent manner (Fig. 1B) . The obvious accumulation of HIF-1 α protein was observed when cells were treated with over 100 μ M CoCl 2 . In CoCl 2 -untreated cells, bcl-2 shRNA was produced by both CMV and HRE-CMV promoter (Fig. 1C) , but there was no significant difference between the amount of shRNA driven by CMV and HRE-CMV promoters. On the other hand, in CoCl 2 -treated cells, the production of bcl-2 shRNA driven by HRE-CMV promoter was significantly greater than that driven by CMV promoter without HREs (Fig. 1C) . The amounts of bcl-2 shRNA driven by HRE-CMV promoter were approximately 2-fold higher than those by CMV promoter ( P < 0.05).
We next investigated whether HRE-CMV promoter also enhanced the gene-silencing effect of bcl-2 shRNA. Transfection of cells with shRNA expression vectors using a polycationic lipid reagent resulted in a significant, but not a considerable, reduction of bcl-2 expression. The reduction of bcl-2 expression was probably due to the harmful effect of plasmid transfection on cell viability (Supplementary Fig. 1 : available in the online version only). However, the decrease in cell viability did not hinder the gene-silencing effect of shRNA expression vectors. CoCl 2 treatment significantly decreased the mRNA levels of bcl-2 in HRE-CMV shbcl-2-transfected colon-26 cells ( P < 0.05, Fig. 2A ). The mRNA levels of bcl-2 in HRE-CMV shbcl-2-transfected colon-26 cells were approximately 70% lower than those in CMV shbcl-2-transfected cells. The transfection of cells with HRE-CMV shbcl-2 also suppressed the expression of Bcl-2 protein (Fig. 2B) . These results suggest that under hypoxic conditions, HRE-CMV shbcl-2 can efficiently suppress the expression of bcl-2 in colon-26 cells. The suppressive effect of HRE-CMV shbcl-2 on the expression of bcl-2 appeared to be specific because the transfection of cells with HRE-CMV shlacZ vectors (negative control) had little effect on the levels of bcl-2 mRNA (Fig. 2A) . Furthermore, neither HRE-CMV shbcl-2 nor CMV shbcl-2 induced the expression of the gene encoding oas1b as an index of interferon response (Supple- . It is thus unlikely that the suppressive effect of HRE-CMV shbcl-2 on the expression of the bcl-2 gene is due to nonspecific action.
HRE-CMV promoter enhances gene-silencing effects of bcl-2 shRNA in hypoxic colon-26 cells implanted in mice
Although HIF-1 α protein is undetectable in most cell types because of rapid degradation by the ubiquitin-proteasome system, hypoxia induces significant accumulation of HIF-1 α protein (28 -31) . As shown in Fig. 3A , extensive expression of HIF-1 α protein was observed in colon-26 tumor cells implanted in mice. The accumulation of HIF-1 α protein seemed to reflect the hypoxic response of the tumor cells. The mRNA levels of bcl-2 in tumor cells implanted in mice were significantly decreased 2 days after a single intratumoral injection of HRE-CMV shbcl-2 (40 μ g/mouse) ( P < 0.05, Fig. 3B ). However, a single intratumoral injection of CMV shbcl-2 (40 μ g/mouse) had little effect on the bcl-2 mRNA level (Fig. 3B) .
HRE-CMV promoter-driven bcl-2 shRNA causes apoptotic cell death and suppression of tumor growth
In the final set of experiments, we explored whether HRE-CMV shbcl-2 could exert apoptotic and anti-tumor activities in tumor-bearing mice. Three days after a single intratumoral injection of HRE-CMV shbcl-2 (40 μ g/ mouse), obvious apoptotic cell death was observed in tumor masses (Fig. 4A) . The numbers of TUNEL-positive cells in HRE-CMV shbcl-2-injected tumor masses were much higher than in CMV shbcl-2-injected tumor masses. The induction of apoptotic cell death seemed to be associated with the gene-silencing effect of bcl-2 shRNA because a few TUNEL-positive cells were noticed in HRE-CMV shlacZ-injected tumor masses.
To explore the ability of HRE-CMV shbcl-2 to suppress tumor growth, tumor-bearing mice received intratumoral injections of HRE-CMV shbcl-2 (40 μ g/mouse) once every other day because significant suppression of bcl-2 mRNA expression in tumor cells implanted in mice was observed 2 days after a single intratumoral injection of HRE-CMV shbcl-2 (Fig. 3B) . As shown in Fig. 4B , the growth of tumor cells implanted in mice was significantly suppressed by HRE-CMV shbcl-2 treatment. Twenty days after the initiation of treatment, the volume of tumor masses in mice treated with HRE-CMV shbcl-2 was significantly smaller than in mice treated with CMV shbcl-2 or with HRE-CMV shlacZ ( P < 0.01, respectively). These results suggest that in hypoxic tumor cells, HRE-CMV shbcl-2 effectively suppresses tumor growth through the induction of apoptotic cell death.
Discussion
In the present study, we focused on a hypoxia-induced transcriptional mechanism in tumor tissue and constructed a hypoxia-response shRNA expression vector to treat cancer. Accumulation of HIF-1 α protein is a marker of the hypoxic response of cells. Cobalt and other divalent metals have been used as hypoxic mimics (32 -34) . In fact, exposure to these metals leads to HIF-1 α stabilization and HIF-1 α -dependent transcription. However, metal exposure can also lead to cellular damage and premature cell death. Although CoCl 2 is not really a hypoxic stimuli, we used this metal to accumulate HIF-1 α (32, 35) . We thus used 100 μ M CoCl 2 to induce the hypoxic condition in cultured cells. HRE-CMV promoter could produce a large amount of bcl-2 shRNA as compared to CMV promoter; however, in CoCl 2 -untreated cells, the production of bcl-2 shRNA by HRE-CMV promoter was not enhanced. It has been suggested that HRE-mediated transcriptional activity is dependent on the number of HRE under the hypoxic condition (36) . Our constructed HRE-CMV promoter contains four HREs, which seemed sufficient to enhance the response to hypoxic stimuli.
A single intratumoral injection of HRE-CMV shbcl-2 into tumor-bearing mice caused a transient decrease in mRNA levels of bcl-2, probably due to the gene-silencing effect of shRNA. The transient bcl-2 mRNA suppression by HRE-CMV shbcl-2 rebounded to the basal level on day 4 after intratumoral injection (Fig. 3B) . This rebound may be explained by the degradation of plasmid vector in apoptotic cells induced by bcl-2 shRNA. In apoptotic cells, chromosomal DNA is degraded by caspase-activated DNase (37) . In this study, apoptosis in tumor masses was induced on day 3 after intratumoral injection of HRE-CMV shbcl-2. Therefore, plasmid vector was degraded during the apoptosis process of tumor cells injected with HRE-CMV shbcl-2. On the other hand, a single intratumoral injection of CMV shbcl-2 had little effect on mRNA levels of bcl-2 in tumor cells. The inability of CMV shbcl-2 to suppress the expression of bcl-2 mRNA is attributable to its low activity of shRNA production. Although CMV promoter could produce bcl-2 shRNA under both hypoxia and normoxia conditions, the amount of shRNA production by CMV promoter in CoCl 2 -treated cells was significantly lower than that driven by HRE-CMV promoter.
Intratumoral injections of HRE-CMV shbcl-2 once every other day, five times into tumor-bearing mice resulted in a significant suppression of tumor growth, whereas the same dosing schedule of CMV shbcl-2 did not suppress tumor growth. This antitumor effect of HRE-CMV shbcl-2 seems to be caused by apoptotic cell death induced by the bcl-2 gene-silencing effect. Although the treatment of tumor-bearing mice with HRE-CMV shbcl-2 had a significant anti-tumor effect, this treatment had little effect on the gain of mouse body weight, as an index of adverse effects ( Supplementary  Fig. 3 : available in the online version only). These results suggest that HRE-CMV shbcl-2 exerts its anti-tumor activity in hypoxic cells without causing severe side effects.
The suppressive effect of HRE-CMV shbcl-2 on the expression of bcl-2 mRNA was observed only on day 2 after the vector injection. Although we tried to explore whether the anti-tumor effect of HRE-CMV shbcl-2 was also observed by injecting the vector (40 μ g/mouse) into tumor-bearing mice every fourth day, four times, the dosing schedule of HRE-CMV shbcl-2 showed no significant anti-tumor activity ( Supplementary Fig. 4 : available in the online version only). This phenomenon may be explained by the short half-life of the shRNA expres- Arrows indicate the injection of each shRNA expression vector. Each point is the mean ± S.E.M. of 6 mice. ** P < 0.01, comparison between the CMV shbcl-2 group and the HRE-CMV shbcl-2 group by ANOVA and the Bonferroni/Dunn test. sion plasmid. Consequently, repetitive administration is required to obtain a significant anti-tumor effect induced by HRE-CMV shbcl-2.
The present results suggest that the approach using both high transfection efficiency and a consecutive transfection system are important to apply RNAi for clinical cancer therapy. Accordingly, RNAi therapy for cancer requires high transfection efficiency to obtain an antitumor effect. RNAi plasmid vectors induce the genesilencing effect only in transfected cells. In other words, untransfected cells fail to show the gene-silencing effect and allow tumor cells to proliferate. In the present study, the decrease in mRNA levels of bcl-2 induced by HRE-CMV shbcl-2 was transient and mRNA returned to the basal level within 4 days after the vector injection. The duration of the gene-silencing effect of bcl-2 shRNA seems to be dependent on the half-life of HRE-CMV shbcl-2. Consecutive transfection of shRNA expression vectors in their target cells is essential to gain a continuous anti-tumor effect in clinical situations.
The present study demonstrates that the insertion of HREs upstream of CMV promoter is useful to enhance shRNA production in hypoxic tumor cells. HIF-1/HRE transcriptional system participates in tumor cell proliferation, aggravation, and metastases in 70% of human cancers, especially solid tumors (38) , suggesting that HRE-CMV promoter could be applied widely to treat various cancers. Because obvious accumulation of HIF-1 protein was observed in tumors, but not in normal tissues, HRE-CMV promoter-driven shRNA expression vector has a controlling effect on shRNA production, which could prevent the disruption of physiological functions in normal tissues. These results may contribute to the investigation of greater efficiency and safety in gene therapy.
